Finding new drugs to stop tau protein buildup in Alzheimer's disease
Official title: Development and validation of a high throughput screening assay for identification of tau aggregation inhibitors in Alzheimer's disease
Funded at University of Texas Hlth Sci Ctr Houston · NIH-10872912 · Data updated 2026-11-12
This study is looking for new drugs that can stop tau proteins from clumping together in the brain, which is important for finding better treatments for Alzheimer's disease, so that patients can have more options to help slow down the effects of the illness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $371,919 |
| NIH project number | 1R61NS136666-01 |
| Project ID | NIH-10872912 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia unrelated to tau pathology may not benefit from this research.
What this research studies
This research focuses on developing a new method to identify drugs that can inhibit the aggregation of tau proteins, which are linked to the progression of Alzheimer's disease. Using a technique called protein misfolding cyclic amplification (PMCA), the researchers aim to create a high-throughput screening assay that can efficiently test potential tau inhibitors. By understanding how tau aggregates form and spread in the brain, the study seeks to discover effective treatments that could slow down or halt the neurodegeneration associated with Alzheimer's. Patients may benefit from new therapeutic options that target the underlying mechanisms of the disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly slow the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in targeting tau aggregation, but this specific approach using PMCA is relatively novel.
Where this research is happening
-
University of Texas Hlth Sci Ctr Houston
Houston, United States Active
Researchers
- Principal investigator: Soto, Claudio — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Soto, Claudio
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.